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day for 5 days) or a conventional therapy group (intrave-
nous/oral regimen of LVFX at 500 mg/day for 7–14 days). 
The clinical, laboratory, and microbiological results were 
evaluated for efficacy and safety.
Results The median dose of LVFX was 3555.4 mg in the 
short-course therapy group and 4874.2 mg in the conven-
tional therapy group. Intention-to-treat analysis indicated 
the clinical effectiveness in the short-course therapy group 
(89.87%, 142/158) was non-inferior to that in the conven-
tional therapy group (89.31%, 142/159). The microbio-
logical effectiveness rates were also similar (short-course 
therapy: 89.55%, 60/67; conventional therapy: 86.30%, 
63/73; p > 0.05). There were no significant differences 
Abstract 
Objective To compare the efficacy and safety of short-
course intravenous levofloxacin (LVFX) 750 mg with a 
conventional intravenous/oral regimen of LVFX 500 mg in 
patients from China with complicated urinary tract infec-
tions (cUTIs) and acute pyelonephritis (APN).
Methods This was a prospective, open-label, randomized, 
controlled, multicenter, non-inferiority clinical trial. 
Patients with cUTI and APN were randomly assigned to a 
short-course therapy group (intravenous LVFX at750 mg/
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in other parameters, including clinical and microbiologi-
cal recurrence rates. The incidence of adverse effects and 
drug-related adverse effects were also similar for the short-
course therapy group (21.95%, 36/164; 18.90%, 31/164) 
and the conventional therapy group (23.03%, 38/165; 
15.76%, 26/165).
Conclusion Patients with cUTIs and APN who were given 
short-course LVFX therapy and conventional LVFX ther-
apy had similar outcomes in clinical and microbiological 
efficacy, tolerance, and safety. The short-course therapy 
described here is a more convenient alternative to the con-
ventional regimen with potential implication in anti-resist-
ance and cost saving.
Keywords Levofloxacin · Complicated urinary tract 
infection (cUTI) · Acute pyelonephritis (APN) · Non-
inferiority trial
Introduction
Urinary tract infection (UTI) is one of the most common bac-
terial infections and is particularly common in women [1]. 
Complicated UTIs (cUTIs) and acute pyelonephritis (APN), 
a subset of cUTI, are treated by management of the under-
lying functional or structural abnormality, administration of 
appropriate antibiotics, and symptom management with or 
without hospitalization [2]. cUTIs can lead to bacteremia 
and are associated with a high mortality rate. Prolonged or 
repeated administration of antibiotics is required for the treat-
ment of cUTIs, but this can lead to the development of anti-
biotic resistance. Extended spectrum β-lactamase (ESBL)-
producing Escherichia coli is the most common pathogen 
responsible for cUTIs, but many other Gram-negative and 
Gram-positive species have been isolated from patients [3], 
and the prevalence of different pathogens depends on patient 
sex and the presence of uncomplicated UTI or cUTI. Qui-
nolones are the drug of choice for treatment of cUTIs, but 
E. coli has a ciprofloxacin resistance rate as high as 58.3% 
in China [4]. There is currently no consensus on the optimal 
therapeutic regimen for the treatment of cUTIs while pre-
venting the development of drug resistance.
Levofloxacin (LVFX) is a quinolone that is widely used 
to treat cUTIs and APN [5]. There are several therapeutic 
regimens that employ LVFX for treatment of these infec-
tions. A study of patients with APN indicated that a high-
dose and short-term LVFX regimen (750 mg/day for 5 days) 
was non-inferior to a standard ciprofloxacin regimen (twice 
daily for 10 days) [6]. The USA has approved a high-dose 
and short-term LVFX regimen for the treatment of cUTIs, 
APN, and other infectious diseases [7]. Pharmacokinetic 
and pharmacodynamic studies of LVFX have confirmed that 
its therapeutic efficacy depends on the dose and the ratio of 
the area under the time–concentration curve to the minimum 
inhibitory concentration (AUC/MIC) [8]. This is considered 
a key pharmacodynamic parameter that determines the opti-
mal bactericidal activity and prevents the development of 
resistance. There is also evidence that the increased ratio of 
peak plasma concentration of LVFX to MIC (Cmax/MIC) 
can prevent the development of resistance [9–11]. Other 
research showed that an oral regimen of LVFX at 750 mg 
per day doubles the serum AUC and Cmax relative to an 
oral regimen of LVFX at 500 mg per day [12, 13].
The duration of LVFX therapy is important for improving 
efficacy and reducing the development of resistance. Thus, 
short-term therapy with LVFX at a high dose (750 mg/day 
for 5 days) may be preferable to a more prolonged treatment 
with a lower dose [6, 14]. In addition, a short-term and high-
dose LVFX regimen may require fewer medical resources 
and improve patient outcomes. However, limited data on 
this regimen are available for patients in China.
This study compared the efficacy and safety of intra-
venous LVFX at 750 mg per day for 5 days with an intra-
venous/oral regimen of LVFX at 500 mg per day for 




This was a prospective, open-label, controlled, multi-
center study that recruited patients from 16 clinical cent-
ers between October 2012 and July 2014. This trial was 
conducted according to the Helsinki guidelines and the 
guidelines for Chinese Good Clinical Practice (GCP). All 
patients provided informed consent for participation.
Study population
Study subjects were male or female patients who were at 
least 18 years old, were inpatients (n = 196) or outpatients 
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(n = 121), had diagnoses of cUTI or APN (females only) 
[8], and were willing to participate in this study and coop-
erate with clinicians, based on the provision of informed 
consent. Patients who failed after 72 h therapy with other 
non-quinolone antibiotics were eligible as well.
Patients were excluded if they were pregnant, breast-
feeding, or preparing for pregnancy during study period; 
received other systemic antimicrobial therapy due to a 
UTI; required or received a long-lasting indwelling cath-
eter; had complete urinary tract obstruction; had urinary 
tract tumors; received urinary tract surgery or lithotripsy 
(due to renal calculus) in the 7 days before study onset; had 
a history of epilepsy; had a history of quinolone-induced 
tendon lesions; had a history of prolonged QT interval and/
or prolonged QT interval on recruitment; were allergic to 
levofloxacin or other quinolones; received any antibiotic 
therapy within 72 h before study onset and if their condi-
tion improved within 72 h before study onset; had severe 
heart disease, liver disease (≥2 times upper limit of normal 
liver enzymes), or pre-existing kidney disease (creatinine 
clearance <50 mL/min), or if the investigators judged the 
patient ineligible; received therapy with at least one drug 
used in this study in the 4 weeks before study onset; had at 
least one health-threatening clinical disease or abnormality 
that could affect the quality of data.
Patients were allowed to exit the study if they wanted to 
withdraw; were lost to follow-up; did not achieve remission 
after 72 h of therapy (although these data were included in 
the final analysis); received therapy with other drugs that 
were not allowed; became pregnant; had any pathologi-
cal event, clinical adverse event, or a physical condition 
that made the clinicians think continued participation was 
incompatible with the best interest of patient.
Drug regimens
Patients were randomly assigned to 2 groups: a LVFX 750 mg 
(5 days) group and a LVFX 500 mg (7–14 days) group. 
Patients in the LVFX 750-mg group received intravenous 
infusion of LVFX (750 mg/150 mL) once daily for 5 con-
secutive days. Patients in the LVFX 500-mg group received 
intravenous infusion of LVFX (500 mg/100 mL) once daily 
and were then shifted to an oral regimen of LVFX (500 mg/
tablet) once daily for 7–14 days. The shift from an intrave-
nous to an oral regimen of LVFX was determined according 
to the mitigation of clinical symptoms (fever and other symp-
toms). Drugs were purchased from Daiichi Sankyo.
Evaluation of therapeutic efficacy
The clinical effectiveness rate at the end of therapy (EOT) 
was the major measure of therapeutic efficacy (day 6 + 1 
in the LVFX 750-mg group and day 8–15 in the LVFX 
500-mg group). The clinical efficacy was classified as com-
plete remission, remission, non-remission, and not appli-
cable (NA). The effectiveness rate was calculated based 
on complete remission and remission. Complete remission 
was defined as the complete absence of clinical symptoms 
and signs without further antibiotic therapy. Remission 
was defined as the significant reduction in clinical symp-
toms and signs with a requirement for further antibiotic 
therapy. Non-remission was defined as the deterioration 
or recurrence of clinical symptoms/signs with a require-
ment for further antibiotic therapy. NA was defined as a 
loss to follow-up within 3 days after therapy or use of other 
antibiotic(s) for reasons other than a UTI.
Several secondary parameters were used to evaluate 
therapeutic efficacy. These were: clinical effectiveness 
rate at the EOT and at the second and third hospital vis-
its; microbiological effectiveness rate at the EOT based on 
clearance/suspected clearance, continuance/suspected con-
tinuance, recurrence, replacement, new infection or NA; 
body temperature (BT) at the EOT, and at the second and 
third hospital visits (compared to baseline); time to remis-
sion of clinical symptoms/signs; white blood cell count 
(WBC), C-reactive protein (CRP) level, and erythrocyte 
sedimentation rate (ESR) at the EOT, and at the second 
and third hospital visits (compared to baseline); recurrence 
rate during the follow-up period (9–15 days after the EOT), 
including clinical recurrence rate and microbiological 
recurrence rate. Clinical recurrence refers to the recurrence 
of clinical symptoms and signs. Microbiological recurrence 
refers to positive results (≥104 cfu/mL) in a urine culture at 
any hospital visit after confirmation of bacterial clearance 
by urine culture. Patients with clearance/suspected clear-
ance, replacement, or new infection were included for the 
calculation of the microbiological effectiveness rate.
Safety was evaluated based on abnormal laboratory 
parameters, adverse events, and severe adverse events. The 
correlation between adverse events and antibiotic therapy 
was evaluated and classified as definite, possible, probable, 
probably not, possibly not, and NA. Definite, possible, prob-
able, and NA adverse events were regarded as adverse events 
of antibiotic therapy. The influence of antibiotic therapy on 
vital signs and electrocardiogram results was also evaluated.
Analysis sets
The intention-to-treat (ITT) set included patients who 
received at least one of the above-mentioned therapies and 
had available data. For patients who were not observed dur-
ing the whole study period, the last observation carried for-
ward (LOCF) method was employed. The bacteriological 
ITT (B-ITT) set included patients who were positive in the 
baseline microbiological examination and had a detectable 
pathogen.
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The per-protocol (PP) set included patients who did not 
violate the study protocol. These patients received therapy 
for at least 3 days (second hospital visit) and had data avail-
able for evaluation of therapeutic efficacy. The bacteriolog-
ical PP (B-PP) set included patients who were positive in 
the baseline microbiological examination and had a detect-
able pathogen.
Safety set (SS) included patients who received therapy 
at least once.
Sample size estimation
A review of the literature led to an estimated response rate 
of 76–96% for the LVFX 750 mg regimen and 74–94% 
for the LVFX 500 mg regimen. The non-inferiority mar-
gin for acute pyelonephritis (APN) treatment is 15%. The 
supplemental tables show the sample size per group under 
power 90 or 80% for a one-sided significance level of 2.5% 
(Tables S1 and S2).
Statistical analysis
This was a non-inferiority clinical trial that compared two 
LVFX regimens for treatment of cUTI and APN. The non-
inferiority margin was −15%. Confidence intervals (CIs) 
were estimated to determine the success rates of the 2 
groups. The primary and secondary endpoints were clini-
cal success rate and microbiologic eradication rate, respec-
tively. The Cochran–Mantel–Haenszel (CMH) test was 
used to assess correlations between the different treatment 
groups and among different strains of microbes. For com-
parison of baseline variables, continuous variables with 
normal distributions are presented as means and standard 
deviations, and an independent samples t test was used to 
compare the groups. Continuous variables with skewed 
distributions are presented as medians and inter-quartile 
ranges (IQRs), and the Mann–Whitney U test was used 
to compare the groups. Categorical baseline variables and 
adverse events are presented as counts and percentages and 
compared by a Chi-square test or Fisher’s exact test. Sta-
tistical analyses were performed with IBM SPSS statisti-
cal software version 22 for Windows (IBM Corp., Armond, 
New York, USA). A 2-tailed p value below 0.05 was con-
sidered statistically significant.
Results
Baseline characteristics of study subjects
We assessed 369 patients for eligibility. Based on the inclu-
sion and exclusion criteria and patients’ willingness to par-
ticipate, we enrolled 330 subjects, with 165 in the LVFX 
500-mg group and 165 in the LVFX 750-mg group. A total 
of 122 subjects in LVFX 500-mg group and 125 in LVFX 
750-mg group completed the therapeutic regimens. A total 
of 83 subjects did not complete the study because continu-
ation was incompatible with their best interests, remis-
sion did not occur after 72 h of therapy, they had a desire 
to withdraw, they were lost to follow-up, they received 
therapy with drugs that were not allowed, or other reasons 
(Table 1 and flow diagram Fig. 1).
The baseline characteristics of the LVFX 500 mg and 
LVFX 750-mg groups, including age, gender, height, 
weight, history of allergies, and diagnostic results, were 
similar (p > 0.05 for all comparisons, Table 2). In addition, 
there were 96 inpatients and 63 outpatients in the LVFX 
500-mg group, and 86 inpatients and 58 outpatients in the 
LVFX 750-mg group (p = 0.593). The median treatment 
time (p < 0.001) and median exposure dose (p < 0.001) 
were significantly greater in LVFX 500-mg group. Table S3 
shows the results of urine cultures (performed before initia-
tion of therapy) in the ITT population.
Clinical success rate
ITT analysis indicated the clinical success rate was 89.31% 
in the LVFX 500-mg group and 89.87% in the LVFX 750-
mg group. The 95% CI of the differences between these 
groups was −6.16% to 7.29%, significantly higher than 
the non-inferiority margin of −15% (p < 0.05). PP analy-
sis indicated the clinical success rate was 90.34% in LVFX 
500-mg group and 93.10% in LVFX 750-mg group. The 
95% CI of the differences between these groups was −3.58 
to 9.09%, also significantly higher than the non-inferiority 
margin of −15% (p < 0.05). Analysis of the clinical suc-
cess rate indicated that the LVFX 500-mg group was not 
Table 1  Disposition of patients with cUTI or APN who were given 
the LVFX 500-mg regimen and the LVFX 750-mg regimen
* Any pathological event, clinical adverse event, or abnormal physi-
cal condition that made investigators consider continued participation 
was incompatible with the best interests of the patient
LVFX 500 mg LVFX 750 mg Total
Number of patients 165 (100.00%) 165 (100.00%) 330 (100.00%)
Completed pro-
tocol
122 (73.94%) 125 (75.76%) 247 (74.85%)
Withdrew 43 (26.06%) 40 (24.24%) 83 (25.15%)
Not in best inter-
ests*
10 (6.06%) 12 (7.27%) 22 (6.67%)
No remission after 
72 h
12 (7.27%) 8 (4.85%) 20 (6.06%)
Withdrawal 7 (4.24%) 10 (6.06%) 17 (5.15%)
Loss to follow-up 8 (4.85%) 2 (1.21%) 10 (3.03%)
Others 6 (3.64%) 8 (4.85%) 13 (3.94%)
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inferior to the LVFX 750-mg group. The clinical success 
rates were significantly better for APN than for cUTI in 
both the LVFX 500-mg group and the LVFX 750-mg group 
(p < 0.05 for both comparisons) (Table 3).
Microbiologic eradication rate
ITT analysis indicated the microbiologic eradication rate 
was 86.30% in the LVFX 500-mg group and 89.55% in 
the LVFX 750-mg group (p > 0.05). The microbiologic 
eradication rate was significantly higher for APN than for 
cUTI in the LVFX 500-mg group (100 versus 72.97%, 
p = 0.003), but not in the LVFX 750-mg group (p > 0.05) 
(Table 4).
Clinical success time and time after last treatment
The median clinical success time was 4 days in the LVFX 
500-mg group and 3 days in the LVFX 750-mg group 
(p > 0.05) (Fig. 2). Moreover, efficacy improved after ces-
sation of treatment, especially in the LVFX 750-mg group 
(Fig. 3).
Safety assessment
The total adverse event rate was 23.03% in the LVFX 
500-mg group and 21.95% in the LVFX 750-mg group 
(p > 0.05) (Table 5). Analysis of all adverse events in LVFX 
500-mg group indicated that 15.76% were associated with 
Fig. 1  Flow diagram
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the study drug, 1.21% were severe adverse events, and 
6.06% were associated with withdrawal from the study. 
Analysis of all adverse events in LVFX 750-mg group indi-
cated that 18.90% were associated with the study drug, 
0.61% were severe adverse events, and 6.71% were asso-
ciated with withdrawal from the study. The two groups 
had no significant differences in any individual adverse 
events or examination results (p > 0.05 for all comparisons) 
(Table 5).
Table 2  Baseline characteristic 
of patients with cUTIs and 
APN who were given the LVFX 
500 mg regimen and the LVFX 
750 mg regimen
Variable LVFX 500 mg LVFX 750 mg p value
(N = 159) (N = 158)
Age (years), mean ± SD 50.18 ± 17.42 49.08 ± 17.37 0.574
Sex 0.512
 Male 22 (13.84%) 18 (11.39%)
 Female 137 (86.16%) 140 (88.61%)
Height (cm), mean ± SD 160.78 ± 6.08 161.17 ± 6.07 0.572
Weight (kg), mean ± SD 59.68 ± 9.74 60.65 ± 10.76 0.404
History of allergies 20 (12.58%) 16 (10.13%) 0.491
Diagnostic result 0.697
 cUTI 90 (56.6%) 86 (54.43%)
 APN 69 (43.4%) 72 (45.57%)
Source 0.593
 Inpatients 96 (60.38%) 100 (63.29%)
 Outpatients 63 (39.62%) 58 (36.71%)
Treatment time (days), median (IQR) 9 (7, 13) 5 (5, 5) <0.001
Exposure dose (mg), median (IQR) 4500 (3500, 6500) 3750 (3750, 3750) <0.001
Table 3  Clinical success rate based on intention-to-treat analysis and per-protocol analysis
The P value was < 0.05 (0.0234) for the difference between APN and cUTI of LVFX 500 mg
* Including patients who achieved complete success and remission
# p < 0.05, significantly different for patients with APN and cUTI
Clinical success rate* ITT PPS
LVFX 500 mg# LVFX 750 mg# LVFX 500 mg LVFX 750 mg
N = 159 N = 158 N = 145 N = 145
APN 95.65% (66/69) 95.83% (69/72)
cUTI 84.44% (76/90) 84.88% (73/86)
Clinical success rate 89.31% (142/159) 89.87% (142/158) 90.34% (131/145) 93.10% (135/145)
Difference of clinical success (95% CI) 0.57 (−6.16,7.29) 2.76 (−3.58, 9.09)
Table 4  Microbiologic eradication rates of APN and cUTI in patients 
given the LVFX 500 mg regimen and the LVFX 750 mg regimen
*p < 0.05, significantly better effectiveness against APN than cUTI
Diagnosis LVFX 500 mg* LVFX 750 mg p value
APN 100.00% (36/36) 91.67% (33/36)
cUTI 72.97% (27/37) 87.10% (27/31)
Effectiveness 86.30% (63/73) 89.55% (60/67) 0.556
Fig. 2  Time course of clinical success for patients in the LVFX 500-
mg group and the LVFX 750-mg group*
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Discussion
The present study compared the safety and efficacy of a 
short-term and high-dose LVFX regimen (750 mg/day for 
5 days) with a routine LVFX regimen (500 mg/day plus 
oral regimen of LVFX for 7–14 days) for the treatment 
of patients with cUTI or APN. This study is the first and 
largest of its kind for the Chinese population to examine 
this short-term and high-dose treatment regimen for the 
most common type of bacterial infection [1]. The results 
showed that these two therapies had similar clinical effi-
cacy, microbiological efficacy, and tolerance. These results 
indicate that the short-term and high-dose LVFX therapy 
that is approved in China and the USA [14] is also suitable 
for patients in Asia with cUTIs or APN. The results of the 
present study also indicate that the therapeutic effective-
ness of each regimen continued for at least 7 days after dis-
continuation and that this effect was more obvious for the 
LVFX 750-mg regimen. Taken together, these results sup-
port the efficacy and safety of the LVFX 750-mg regimen.
Another important finding of the present study is that 
the total duration of the LVFX 750 mg regimen was 50% 
shorter and the total dose of the LVFX 750 mg regimen 
was 27% less. The present study did not compare the costs 
of the different LVFX regimens, but these data strongly 
suggest that the LVFX 750 mg regimen is associated with 
reduced need for medical resources and reduced costs. 
These factors are particularly noteworthy for developing 
countries with large populations and more limited medical 
resources.
There is a very high incidence of quinolone-resistant E. 
coli in China, and the MIC90 of quinolones is as high as 
Fig. 3  Time course of clinical success after the last treatment for 
patients in the LVFX 500-mg group and the LVFX 750-mg group
Table 5  Adverse events among 
patients in the LVFX 500-mg 
group and the LVFX 750-mg 
group
* The correlation between adverse events and drugs was classified as definite, probable, or possible
LVFX 500 mg LVFX 750 mg p value
(N = 165) (N = 164)
N (incidence) N (case-time) N (incidence) N (case-time)
Total 38 (23.03%) 52 36 (21.95%) 57 0.792
Related to drugs* 26 (15.76%) 36 31 (18.90%) 46 0.071
Severe 2 (1.21%) 2 1 (0.61%) 1 1.000
Resulting in loss to follow-up* 10 (6.06%) 10 11 (6.71%) 15 0.686
Examinations 16 (9.70%) 17 14 (8.54%) 17 0.702
Reduction in leukocyte count 9 (5.45%) 9 9 (5.49%) 9 1.000
Reduction in neutrophil count 2 (1.21%) 2 3 (1.83%) 3 1.000
Increased ALT 2 (1.21%) 2 2 (1.22%) 2 1.000
Increased ASP 2 (1.21%) 2 3 (1.83%) 2 1.000
Increased platelet count 2 (1.21%) 2 0 (0%) 0 0.489
Increased blood pressure 0 (0%) 0 1 (0.61%) 1 1.000
Gastrointestinal 4 (2.42%) 6 7 (4.27%) 10 0.358
Reaction at injection site 7 (4.24%) 9 3 (1.83%) 4 0.199
Cutaneous/subcutaneous 3 (1.82%) 2 3 (1.83%) 3 1.000
Nervous system/mental 1 (0.61%) 0 4 (2.44%) 7 0.371
Immune 1 (0.61%) 1 1 (0.61%) 1 1.000
Infection 7 (4.24%) 1 1 (0.61%) 1 0.067
Hepatobiliary 0 (0%) 0 1 (0.61%) 1 1.000
Metabolic/nutritional 1 (0.61%) 0 3 (1.83%) 1 0.623
Musculoskeletal/connective tissue 0 (0%) 0 1 (0.61%) 1 1.000
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16 mg/L for this species [15]. Clinical protocols for treat-
ment of UTIs, especially cUTIs, must be effective against 
E. coli because this species is the most common causative 
agent [16]. The development of new antibiotics has slowed, 
so it is necessary to optimize the regimens of available anti-
biotics to treat UTI and APN. LVFX is a dose-dependent 
antibiotic that is excreted in the urine. High-dose LVFX 
leads to increased concentration in the urine, prolonged 
(8–12 h) activity against E. coli, and efficacy against E. 
coli with MICs up to 32 µg/mL [17]. Although the present 
study did not measure the sensitivity of isolated pathogens 
to LVFX, the bacterial clearance rate in the LVFX 750-mg 
group was higher than in the LVFX 500-mg group among 
patients with cUTIs. This indicates that the LVFX 750 mg 
regimen may achieve better outcomes in cUTI patients.
A 2008 study in the USA compared a LVFX regimen 
(750 mg per day for 5 days) with a ciprofloxacin regi-
men (400/500 mg twice daily for 10 days) for treatment of 
cUTIs and APN [14]. The results showed that these regi-
mens had comparable effectiveness and safety. However, 
the ciprofloxacin regimen described in this previous study 
is probably not suitable for the treatment of cUTI and APN 
in China, where the ciprofloxacin resistance rate for E. 
coli can exceed 50% [4]. A recent study compared a cef-
tolozane–tazobactam regimen with a levofloxacin regimen 
(750 mg/day for 5 days) for treatment of cUTIs and APN 
[18]. The results indicated that the ceftolozane–tazobactam 
regimen was better than the high-dose levofloxacin regi-
men. Although this study enrolled 1083 patients from 209 
sites throughout the world, none of the patients were from 
China. Thus, it remains to be determined whether this cef-
tolozane–tazobactam regimen is also more effective in Chi-
nese patients with cUTIs or APN.
In conclusion, Chinese patients with cUTIs and APN 
who were given intravenous LVFX at 750 mg per day for 
5 days or an intravenous/oral regimen of LVFX at 500 mg 
per day for 7–14 days had similar outcomes in terms of 
clinical and microbiological efficacy, tolerance, and safety. 
The LVFX 750 mg regimen may be preferred for the treat-
ment of these infections because its duration was 50% less 
and the total drug dose was 23% less.
Compliance with ethical standards 
Conflict of interest The authors declare that they have no conflict of 
interest.
Ethical approval This trial was conducted according to the Helsinki 
guidelines and the guidelines for Chinese Good Clinical Practice 
(GCP). All patients provided informed consent for participation.
Open Access This article is distributed under the terms of the 
Creative Commons Attribution 4.0 International License (http://
creativecommons.org/licenses/by/4.0/), which permits unrestricted 
use, distribution, and reproduction in any medium, provided you give 
appropriate credit to the original author(s) and the source, provide a 
link to the Creative Commons license, and indicate if changes were 
made.
References
 1. Foxman B (2003) Epidemiology of urinary tract infections: inci-
dence, morbidity, and economic costs. Dis Mon 49:53–70
 2. Singh KP, Li G, Mitrani-gold FS et al (2013) Systematic review 
and meta-analysis of antimicrobial treatment effect estimation in 
complicated urinary tract infection. Antimicrob Agents Chem-
other 57:5284–5290
 3. Moriel DG, Schembri MA (2013) Vaccination approaches for 
the prevention of urinary tract infection. Curr Pharm Biotechnol 
14:967–974
 4. Hu FP, Zhu DM, Wang Fu et al (2014) CHINET 2013 surveil-
lance of bacterial resistance in China. Chin J Infect Chemother 
14:365–374
 5. Mcgregor JC, Allen GP, Bearden DT (2008) Levofloxacin in the 
treatment of complicated urinary tract infections and acute pye-
lonephritis. Ther Clin Risk Manag 4:843–853
 6. Klausner HA, Brown P, Peterson J et al (2007) A trial of levo-
floxacin 750 mg once daily for 5 days versus ciprofloxacin 
400 mg and/or 500 mg twice daily for 10 days in the treatment of 
acute pyelonephritis. Curr Med Res Opin 22:2637–2645
 7. Anderson VR, Perry CM (2008) Levofloxacin: a review of its 
use as a high-dose, short-course treatment for bacterial infection. 
Drugs 68:535–565
 8. Richard GA, Klimberg IN, Fowler CL et al (1998) Levofloxacin 
versus ciprofloxacin versus lomefloxacin in acute pyelonephritis. 
Urology 52:51–55
 9. Blaser J, Stone BB, Groner MC et al (1987) Comparative study 
with enoxacin and netilmicin in a pharmacodynamic model to 
determine importance of ratio of antibiotic peak concentration to 
MIC for bactericidal activity and emergence of resistance. Anti-
microb Agents Chemother 31:1054–1060
 10. Drusano GL, Johnson DE, Rosen M et al (1993) Pharmacody-
namics of a fluoroquinolone antimicrobial agent in a neutropenic 
rat model of Pseudomonas sepsis. Antimicrob Agents Chemother 
37:483–490
 11. Forrest A, Nix DE, Ballow CH et al (1993) Pharmacodynamics 
of intravenous ciprofloxacin in seriously ill patients. Antimicrob 
Agents Chemother 37:1073–1081
 12. Gotfried MH, Danziger LH, Rodvold KA (2001) Steady-state 
plasma and intrapulmonary concentrations of levofloxacin and 
ciprofloxacin in healthy adult subjects. Chest 119:1114–1122
 13. Lister PD (2002) Pharmacodynamics of 750 mg and 500 mg 
doses of levofloxacin against ciprofloxacin-resistant strains of 
Streptococcus pneumoniae. Diagn Microbiol Infect Dis 44:43–49
 14. Peterson J, Kaul S, Khashab M et al (2008) A double-blind, 
randomized comparison of levofloxacin 750 mg once-daily for 
5 days with ciprofloxacin 400/500 mg twice-daily for 10 days for 
the treatment of complicated urinary tract infections and acute 
pyelonephritis. Urology 71:17–22
 15. Zhang YY, Huang HH, Ren ZY et al (2009) Clinical evaluation of 
oral levofloxacin 500 mg once-daily dosage for treatment of lower 
respiratory tract infections and urinary tract infections: a prospec-
tive multicenter study in China. J Infect Chemother 15:301–311
 16. Moriel DG, Schembri MA (2013) Vaccination approaches for 
the prevention of urinary tract infection. Curr Pharm Biotechnol 
14:967–974
507Int Urol Nephrol (2017) 49:499–507 
1 3
 17. Stein GE, Schooley SL, Nicolau DP (2008) Urinary bacterial 
activity of single doses (250,500,750 and 1000 mg) of levofloxa-
cin against fluoroquinolone-resistant strains of Escherichia coli. 
Inter J Antimicrobial Agents 32:320–325
 18. Wagenlehner FM, Umeh O, Steenbergen J et al (2015) Ceftolozane-
tazobactam compared with levofloxacin in the treatment of compli-
cated urinary-tract infections, including pyelonephritis: a randomised, 
double-blind, phase 3 trial (ASPECT-cUTI). Lancet 385:1949–1956
